The Private Sector Investment Conundrum
If new classes of antibiotics are to be used sparingly or squirrelled away for last use, why invest in their development? This conundrum - in which the old model of volume-based reimbursement is failing - sits at the heart of why pharma companies are no longer interested in investing in antibiotics, and why the pipeline is so weak. Several initiatives have sought to identify "pull" incentives that will reward successful R&D outcomes and thereby persuade pharma to re-engage in drug development. So far, industry remains unconvinced, and governments are reluctant. Yet solving this market failure is a matter of urgency. What incentives show the most potential, and can they be made to work?
Head of AMR Policy and Advocacy and Lead for Strategic Planning, IFPMA
26th Mar 2019
11:50 to 12:30 UTC±00:00
20 Tavistock Square, Bloomsbury, London WC1H 9HW